This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/3/2026
Ladies and gentlemen, thank you for standing by. Welcome to Rhythm Pharmaceuticals' third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you would need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. And to withdraw your question, please press star 1-1 again. We ask that you please limit to one question. Please be advised that today's conference is being recorded. I would now like to turn the call over to Dave Connolly, Head of Investor Relations. Please go ahead.
Thank you, Michelle. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investor section of our website, ir.rhythmtx.com. Last night, we issued a press release announcing the amendment to our Bivomelagon licensing agreement, and this morning, we issued our press release that provides our Q3 2026 financial results and a business update. Both press releases are available on our website. Our agenda is listed on slide two. On the call today are David Meeker, our Chairman, Chief Executive Officer, and President, Jennifer Lee, Executive Vice President, Head of North America, Hunter Smith, Chief Financial Officer, and Yann Mazabraud, Executive Vice President, Head of International, is on the line joining us from Europe. On slide 3, I'll remind you this call contains remarks concerning future expectations, plans, and prospects, which constitute forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent annual or quarterly reports on file with the SEC. In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent dates. We specifically disclaim any obligation to update such statements. With that, I'll turn the call over to David Meeker, who will begin on slide five.
Thank you, Dave. Good morning, and thank you for joining today. Rhythm continues to execute on multiple fronts, and we are excited to update you on our progress. So let's start on slide five. We are very pleased to announce a strong third quarter driven by an excellent start to the U.S. launch. Start forms are growing, as expected, with encouraging market access translating to strong revenue performance of $92 million for the quarter. Jennifer will provide more details. We are excited about launching in Japan with the first commercial patients already on treatment. We have every expectation that Japan will become our second largest market. Yann will provide more color there. I will say more about our clinical development plans in the recently announced amendment to our LG Chem deal over the next couple slides. Slide six is a reminder of our three major strategic pillars. The first pillar is the genetic indications, where we have multiple approvals and we will be looking to expand the list of genes we are investigating. More to come on that in 2027. Second is HO, where we have a growing conviction in the magnitude of this opportunity globally, as you will hear more about today. Third is Prader-Willi syndrome, a devastating genetic disease with only one approved therapy in the U.S. and a desperate need for more treatment options. Let me spend a minute on why PWS is so strategically important to rhythm and why we believe we can make a meaningful difference in this disease. I often draw the analogy to where the cystic fibrosis community was at the time the first disease-modifying treatments were being approved. Like CF, PWS patients are almost universally diagnosed at birth. The newborn is hypotonic, floppy, which leads to early genetic testing. Average survival is age 30, which speaks to the severe unmet medical need, and providing care for these patients is challenging for their families, the healthcare system, and society as a whole. The PWS community is well organized with a strong patient organization, specialized clinics, staffed by experienced clinicians providing these patients with greater access to the healthcare system than many patients with HO, for example, who still don't have a diagnosis. It is a complex genetic disease with multiple genes involved, but central to the disease is impaired signaling through the MC4R pathway. The six-month Phase II data Dr. Miller presented at ENDO in June showing a reduction in hyperthasia scores, anxiety scores, and BMI values supports the potential role of an MC4R precision agonist in the management of this disease. Now, I will extend the CF analogy one step further. Vertex recognized with their first approval in CF that they had a unique ability to make a major difference in this disease. So they literally doubled and tripled down on trying to optimize outcomes. Our strategy will be similar. We will run our first phase three trial with Bivomelagon, but with the expectation given the size and importance of this opportunity, we would develop both of our next generation therapies in this disease. As previously indicated, the decision to start with Bivomelicon has some practical aspects, most specifically related to CMC and availability of supply. We simply have an ability to start earlier than we would with 718. Furthermore, as with CF, we expect a monotherapy to work and be approved, but given the complexity of the disease, optimal outcomes will be achieved by combination therapies. We are not prepared to discuss our portfolio at this time. We will do that in 2027. But the message today is simply that we are working to develop the best possible approach to MC4R diseases based on our understanding of the biology, and that will include proprietary combination approaches. Moving to slide seven, we're excited to initiate our Phase III Bisomelagon-HO study. This is a 52-week comparably sized study to the original Transcend study with BMI as the primary endpoint. We hope to begin screening patients at the first sites by the end of the year and expect to dose the first patients in January. With a decision to proceed with Bivomelagon in PWS, we will now engage with regulators with the goal of initiating a six-month phase three study in PWS with hyperphasia as measured by HQCT as a primary endpoint in 2027. I want to provide a shout out to the rhythm teams who have not been idle on the development front. In preparation for the Phase VIVA Phase III studies, we needed to complete the following. A bioequivalent study with a new formulation, a food effect study, a drug-drug interaction study, and a hepatic impairment study, all of which have been completed satisfactorily in the past year, further de-risking Bivomelagon as a core asset as we move into Phase III trials. Finally, a brief word about a recently announced amendment of the LG Chem deal. Our decision to amend was driven by two factors. First, our growing belief in the overall opportunity related to MC4R pathway diseases, giving us the confidence to buy down the existing royalty. And secondly, the original structure, despite our best efforts to align the two companies' interests, left us with an economic disincentive to fully develop Vivimelagon, as that would drive a disproportionate royalty burden relative to developing 7181. In the current structure, we are fully aligned and can simply, as we would want to do, follow the science and develop the best possible treatment for the indication. I remind you that the patent protection for both BIV and 718 extends into the 2040s, providing sustainable long-term value for shareholders. Hunter will provide more details on the LG transaction. I'll now turn the call over to Jen.
You're reading a preview of the RYTM Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing